Forest Labs,Replidyne terminate US faropenem medoxomil deal
Forest Laboratories has licensed rights to develop and market Replidyne's orally bioavailable broad-spectrum antibiotic Orapem (faropenem medoxomil) in the US.
- Specialty Pharmaceuticals
- Includes Contract
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com